- Home
- CNOB vs RCUS Comparison
CNOB vs RCUS Comparison
Compare CNOB & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNOB
- RCUS
- Stock Information
- Founded
- CNOB 1982
- RCUS 2015
- Country
- CNOB United States
- RCUS United States
- Employees
- CNOB N/A
- RCUS N/A
- Industry
- CNOB Major Banks
- RCUS Biotechnology: Pharmaceutical Preparations
- Sector
- CNOB Finance
- RCUS Health Care
- Exchange
- CNOB Nasdaq
- RCUS Nasdaq
- Market Cap
- CNOB 1.3B
- RCUS 1.2B
- IPO Year
- CNOB 1996
- RCUS 2018
- Fundamental
- Price
- CNOB $24.42
- RCUS $18.12
- Analyst Decision
- CNOB Buy
- RCUS Buy
- Analyst Count
- CNOB 1
- RCUS 8
- Target Price
- CNOB $31.00
- RCUS $26.50
- AVG Volume (30 Days)
- CNOB 274.5K
- RCUS 1.2M
- Earning Date
- CNOB 10-30-2025
- RCUS 11-05-2025
- Dividend Yield
- CNOB 2.97%
- RCUS N/A
- EPS Growth
- CNOB N/A
- RCUS N/A
- EPS
- CNOB 0.80
- RCUS N/A
- Revenue
- CNOB $241,854,000.00
- RCUS $262,000,000.00
- Revenue This Year
- CNOB $50.62
- RCUS N/A
- Revenue Next Year
- CNOB $28.54
- RCUS N/A
- P/E Ratio
- CNOB $30.44
- RCUS N/A
- Revenue Growth
- CNOB N/A
- RCUS 6.07
- 52 Week Low
- CNOB $20.61
- RCUS $6.50
- 52 Week High
- CNOB $29.31
- RCUS $18.98
- Technical
- Relative Strength Index (RSI)
- CNOB 46.54
- RCUS 74.20
- Support Level
- CNOB $23.25
- RCUS $16.04
- Resistance Level
- CNOB $24.79
- RCUS $17.67
- Average True Range (ATR)
- CNOB 0.83
- RCUS 1.24
- MACD
- CNOB -0.17
- RCUS 0.23
- Stochastic Oscillator
- CNOB 36.00
- RCUS 94.48
About CNOB ConnectOne Bancorp Inc.
ConnectOne Bancorp Inc is a community-based, full-service New Jersey-chartered commercial bank. Substantially all loans are secured with various types of collateral, including business assets, consumer assets and commercial/residential real estate. Each borrower's ability to repay its loans is dependent on the conversion of assets, cash flows generated from the borrowers' business, real estate rental and consumer wages.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.